A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America
Latest Information Update: 18 Jun 2020
At a glance
- Drugs Flibanserin (Primary)
- Indications Decreased libido; Female sexual dysfunction
- Focus Registrational; Therapeutic Use
- Acronyms VIOLET
- Sponsors Boehringer Ingelheim
- 20 Dec 2015 Results published in the Annals of Pharmacotherapy
- 18 Aug 2015 According to a Sprout Pharmaceuticals media release, the US FDA has approved flibanserin 100 mg (Addyi) for the treatment of acquired generalized hypoactive sexual desire disorder in premenopausal women.
- 04 Jun 2015 According to a Sprout Pharmaceuticals media release, the FDA advisory committee has recommended for approval flibanserin (ADDYI) for the treatment of hypoactive sexual desire disorder in premenopausal women.